Permanent implantation of ~(125)I seeds combined with GP scheme chemotherapy for non-small cell lung carcinoma in aged patients / 介入放射学杂志

ABSTRACT

Objective To assess the feasibility, safety and curative effect of permanent implantation of ~(125)I seeds combined with GP scheme chemotherapy for the treatment of non-small cell lung carcinoma (NSCLC) in aged patients. Methods CT-guided permanent implantation of ~(125)I seeds combined with GP scheme chemotherapy was performed in 46 patients with NSCLC, of whom 26 received primary treatment and 20 underwent renewed treatment. During the procedure, ~(125)I seeds were embedded into the tumor in all the patients. Three to five days after the implantation, GP scheme chemotherapy started. GEM (1 000 mg/m~2) was given (intravenously dripping for 30 min.) on the 1st, 8th and 15th day; DDP (30 mg/m~2) was employed on the 1st, 2nd and 3rd day, and recombinant human endostatin (Endostar, 7.5 mg/m~2) was administered (intravenously dripping for 3-4 hours) from the 1st to the 14th day. Every 28 days completed one treatment course. Two months after ~(125)I seed implantation, at this time the patient had received two courses of treatment, the short-term effect and the toxic side-effect were evaluated. Results Two months after the ~(125)I particles were embedded in the tumor, all the 46 cases were able to be evaluate for the curative effect. Of 46 patients, complete relief (CR) was seen in 12, partial relief (PR) in 24, stable (SD) in 6 and progression (PD) in 4, with an effective rate of 78.26%. Of 26 patients in the primary treatment group, CR was obtained in 7, PR in 15, SD in 3 and PD in 1, with an effective rate of 84.6%. Of 20 patients in the renewed treatment group, CR was seen in 5, PR in 9, SD in 3 and PD in 3, with an effective rate of 70.0%. Conclusion Permanent implantation of ~(125)I seeds combined with GP scheme chemotherapy is an effective, safe and feasible treatment for NSCLC in aged patients.